Global Osteoporosis Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2023

Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis Drugs is a kind of medicine for Osteoporosis, such as Fosamax, Actonel, Boniva, Zoledronic Acid (Reclast or Zometa) and others.

Scope of the Report:
This report focuses on the Osteoporosis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Osteoporosis, which literally means porous bone, is a disease in which the density and quality of bone are reduced. As bones become more porous and fragile, the risk of fracture is greatly increased. The loss of bone occurs silently and progressively. Often there are no symptoms until the first fracture occurs. Osteoporosis drugs are a kind of medicine for Osteoporosis. The types of osteoporosis drugs mainly include antiresorptive drugs and anabolic drugs.

The Brazil osteoporosis drugs is Very concentrated, the sales of top eight manufacturers account exceeds 70% of Brazil sales.

The antiresorptive drugs is the main types of osteoporosis drugs. In 2015, the sales revenue of antiresorptive drugs is about 109 M USD; its proportion of total osteoporosis drugs exceeds 73%.

The worldwide market for Osteoporosis Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Antiresorptive Drugs
Anabolic Drugs

Market Segment by Applications, can be divided into
Female
Male

There are 15 Chapters to deeply display the global Osteoporosis Drugs market.
Chapter 1, to describe Osteoporosis Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Osteoporosis Drugs, with sales, revenue, and price of Osteoporosis Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Osteoporosis Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Osteoporosis Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Osteoporosis Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source